Research & Literature Library
Published clinical studies, systematic reviews, meta-analyses, and active clinical trials supporting the use of biologic therapy across indications. Sources are indexed by PubMed, ClinicalTrials.gov, and peer-reviewed journals.
Primary Research Databases
Access the full indexed literature on exosome and MSC-based biologic therapy directly from source.
Chronic Low Back Pain: MSC Matrix Therapy Outcomes
Three-participant series evaluating paraspinal Perinatal-Derived MSC Matrix therapy for chronic lumbar back pain. Documents VAS score changes and functional improvement through 8 weeks.
View Full Case Study →Knee Osteoarthritis: Combined Biologic Therapy
Perinatal-derived MSC Matrix combined with Chondrocyte-Derived Exosomes intra-articular injection for knee OA. Three participants assessed at 12 weeks with WOMAC and VAS outcomes.
View Full Case Study →Shoulder Pathology: Perinatal MSC Matrix Outcomes
Chondrocyte-Derived Exosomes combined with Perinatal-Derived MSC Matrix for rotator cuff pathology and glenohumeral OA. Standardized 8-week functional and pain outcome assessment.
View Full Case Study →Male Sexual Health: Exosome Complex Efficacy Study
Specialized Exosome Complex intracavernosal exosome injection combined with daily VED therapy. IIEF-EF outcomes and patient satisfaction documented at 12 weeks.
View Full Case Study →MSC-Derived Exosomes for Knee OA: Systematic Review & Meta-Analysis
28 preclinical studies demonstrating consistent therapeutic advantages in cartilage repair across OARSI, Mankin, and ICRS validated scoring systems.
MSC-Exos as Cell-Free Therapy for Knee Osteoarthritis
Comprehensive review of MSC-exosome applications in OA including a completed clinical trial showing significant pain reduction and improved joint function 6 months after injection.
hUC-MSC-Derived Exosomes for Knee OA: Preclinical to Clinical
Clinical trial confirming hUC-MSC-derived exosomes reduce inflammation and promote cartilage regeneration in OA, with demonstrated safety and efficacy in both preclinical and clinical settings.
Phase I: UC-MSC Exosome Intra-Articular Injection in Knee OA
Phase 1 dose-escalation trial evaluating safety of allogeneic UC-MSC small extracellular vesicles delivered by intra-articular injection for mild to moderate symptomatic knee OA.
Exosome-Laden Scaffolds for Post-Traumatic Cartilage Injury
Systematic review of exosome scaffold applications for post-traumatic cartilage injury and OA, evaluating in vitro and in vivo outcomes across multiple delivery approaches.
Neuroprotective Properties of SC-Derived Exosomes: Alzheimer's, Parkinson's & Stroke
Reviews SC-derived exosome mechanisms including crossing the blood-brain barrier, targeting disease pathways, and providing controlled release of neuroprotective agents in AD, PD, and stroke.
MSC & Exosome Therapies in Cognitive Impairment: Alzheimer's & Parkinson's
Review of MSC and MSC-derived exosome therapeutic potential in AD and PD, covering neuroinflammation modulation, neuroprotection, and cognitive outcomes across preclinical and emerging clinical data.
MSC-Derived Exosomes in the Treatment of Parkinson's Disease
Systematic review of MSC-exosome mechanisms in PD including BDNF/GDNF delivery, blood-brain barrier crossing, neuroprotection, and dopaminergic pathway support in animal models.
Anti-Fibrotic Arsenal: MSC-Exosomes in Pulmonary Fibrosis
Review of MSC-exosome anti-fibrotic mechanisms in PF including macrophage polarization, ECM remodeling, and evaluation of completed and ongoing clinical trials 2014–2024.
MSC-EVs in Chronic Respiratory Diseases: COPD, Asthma, IPF
Overview of MSC-derived extracellular vesicle therapeutic potential across COPD, asthma, pulmonary fibrosis, and PAH, covering delivery routes, isolation methods, and mechanisms of action.
Molecular Mechanisms of MSC-Exos in Lung Fibrosis Treatment
Details MSC-exosome anti-fibrotic, anti-inflammatory, and immunoregulatory mechanisms in pulmonary fibrosis, including fibroblast activation suppression and M1-to-M2 macrophage reprogramming.
MSC-Derived EVs in COPD, COVID-19, ARDS & Pulmonary Fibrosis
Reviews MSC-derived EV mechanisms and current understanding of therapeutic applications across COPD, COVID-19, ARDS, IPF, and cystic fibrosis with translational limitations and outlook.
Exosomes & Hair Regeneration: Clinical Evidence Across Alopecia Types
11 clinical studies (2022–2025) including RCTs, prospective and retrospective studies. Consistent improvements in hair density and thickness. No significant adverse reactions reported across studies.
Effectiveness of Exosome Treatment in Androgenetic Alopecia
Prospective study of MSC-derived exosome scalp injection for AGA. Significant increases in hair density and thickness at 6 months. No adverse events recorded.
Exosomes in Trichology: Clinical Studies Summary Table
Descriptive summary of all clinical exosome-based hair loss studies including ADSC-derived and MSC-derived approaches across AGA, alopecia areata, and chemotherapy-induced alopecia.
Exosome Treatment in Hair Restoration: Evidence, Safety & Future Directions
Review covering ADSC-exosome and DPC-derived exosome applications with clinical evidence in 39 AGA patients showing significant hair density and thickness gains. Safety profile favorable across all reviewed studies.
Randomized Trial: Exosome vs. Placebo for Androgenetic Alopecia
Completed prospective RCT evaluating intradermal exosome injection vs placebo for AGA with 30G needle grid administration protocol across 4-week intervals.
SC-Derived Exosome Therapy for Erectile Dysfunction: Preclinical Meta-Analysis
Systematic review and meta-analysis of preclinical ED studies evaluating intracavernous exosome injection. Demonstrates consistent erectile function improvement via VEGF, eNOS, and smooth muscle restoration pathways.
MSC-Exosomes Ameliorate Erection via Oxidative Stress Reduction in Corpus Cavernosum
Demonstrates IC injection of MSC-derived exosomes reduces oxidative damage to corpus cavernosum in arterial injury rat model with similar potency to cell therapy and superior practical advantages.
Phase II: MSC Exosome for Moderate-to-Severe Erectile Dysfunction
Randomized Phase 2 trial of intracavernosal MSC-derived exosome injection for moderate to severe ED non-responsive to PDE5 inhibitors. Weekly injections × 6 weeks protocol.
RISE Trial: ADSC or Exosome Injection for Erectile Dysfunction
Prospective observational study evaluating autologous ADSC or exosome intracavernosal injection for ED non-responsive to standard treatments. Includes post-prostatectomy ED and diabetic ED cohorts.